Evolus, Inc. (NASDAQ:EOLS) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Ned Mitchell - IR Rui Avelar - Chief Medical Officer & Head, Research & Development David Moatazedi - President, CEO & Director Sandra Beaver - CFO Conference Call Participants Louise Chen - Cantor Fitzgerald Annabel Samimy - Stifel, Nicolaus & Company Marc Goodman - Leerink Partners Navann Dietschi - BNP Paribas Exane Uy Ear - Mizuho Securities Douglas Tsao - H.C. Wainwright & Co. Operator Good afte ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _______ ...

Evolus, Inc. (NASDAQ:EOLS) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants David Erickson - VP, IR David Moatazedi - President and CEO Rui Avelar - CMO and Head, Research & Development Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Navann Ty - BNP Louise Chen - Cantor Fitzgerald Doug Tsao - H.C. Wainwright Serge Belanger - Needham & Company Operator Greetings and welcome to the Evolus Second Quarter 2023 Earnings Conference Call. At this time, all pa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ ...

Evolus, Inc. (NASDAQ:EOLS) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants David Erickson - VP, IR David Moatazedi - President and CEO Rui Avelar - CMO and Head, Research & Development Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Marc Goodman - SVB Securities Douglas Tsao - H.C. Wainwright Operator Greetings, and welcome to the Evolus First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ ...

POEVOLUS DESIGNED TO COMPETE Other AEs of Interest • Ptosis (drug-related) • Eyebrow - Jeuveau 0%, Botox 0.4% 10 2 Days 14 Days 30 Days 90 Days 120 Days 150 Days Jeuveau® Botox® 54.5 95.7 95.3 76.7 57.8 37.9 57.4 95.1 93.9 73.9 51.5 34.3 11 Millennials "ORIGINAL" • 20U Jeuveau® Jeuveau® | --- | --- | --- | --- | --- | |-------------------------------------|-------------------------------------------|-----------------------|--------------------|----------------------| | ADVERSE EVENTS | Adverse Event Summary ...

Evolus, Inc. (NASDAQ:EOLS) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants David Erickson - Vice President of Investor Relations David Moatazedi - President and Chief Executive Officer Rui Avelar - Chief Medical Officer and Head of Research and Development Sandra Beaver - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel, Nicolaus & Company, Inc. Marc Goodman - SVB Securities Douglas Tsao - H.C. Wainwright & Co. Louise Chen - Cantor Fitzgerald & Co. ...

Product Commercialization - The company relies entirely on the successful commercialization of its only product, Jeuveau, and failure to market it effectively may hinder revenue generation [16] - Jeuveau's commercial success depends on achieving broad physician adoption and consumer demand, which may not be guaranteed [21] - The reliance on the Daewoong Agreement for exclusive distribution rights is crucial; any loss of these rights would significantly impact Jeuveau's commercialization [21] - Evolus relies on the Daewoong Agreement for exclusive rights to distribute Jeuveau in certain territories, and any loss of these rights could materially affect its commercialization efforts [21] Financial Viability - The company has incurred significant losses since inception and anticipates continued losses for the foreseeable future, complicating future viability assessments [16] - Additional financing may be required to fund future operations, and failure to secure capital could lead to operational delays or reductions [16] Regulatory Challenges - Regulatory approvals are necessary for expanding indications for Jeuveau, which could be costly and not guaranteed [21] - The company’s ability to market Jeuveau is currently limited to treating glabellar lines, necessitating further regulatory approvals for broader applications [21] - Evolus is subject to extensive government regulation, which may result in delays or additional expenses in obtaining regulatory approvals for product candidates [21] Competition - The company faces significant competition in the market, which may impede achieving substantial market penetration and expansion [21] - Jeuveau faces significant competition, and failure to effectively compete may hinder market penetration and expansion [21] Operational Risks - Compliance with settlement agreements with Medytox, Inc. is critical; non-compliance may result in litigation or loss of marketing rights for Jeuveau [16] - The terms of the Settlement Agreement with Medytox will reduce profitability and may limit discount offerings to customers [16] - The company’s operations may be adversely affected by the COVID-19 outbreak or similar events [21] - The COVID-19 outbreak has adversely affected the company’s business, financial condition, and operations, with potential future impacts [21] - The company’s operations are heavily reliant on digital technology, and any system failures or breaches could adversely impact business [21] Growth and Development - Failure to successfully in-license, acquire, develop, and market additional product candidates could impair business growth [21] - Evolus may need to increase its organization size, including sales and marketing capabilities, to further market Jeuveau, which could present management challenges [21] - There is a risk of third-party claims of intellectual property infringement that could delay commercialization efforts [21]

This presentation contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position; business strategy; the market growth for our product; our ability to meet our goals related to the market position of our product; the potential market acceptance, demand market size, adoption rate, revenue exp ...